<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22307" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Gluconeogenesis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Melkonian</surname>
            <given-names>Erica A.</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Asuka</surname>
            <given-names>Edinen</given-names>
          </name>
          <aff>All Saints University School of Medicine, Dominica.</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schury</surname>
            <given-names>Mark P.</given-names>
          </name>
          <aff>McLaren Oakland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Erica Melkonian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Edinen Asuka declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Schury declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22307.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The brain, eye, and kidney are some of the organs&#x000a0;that have glucose as the&#x000a0;sole metabolic fuel source. Prolonged fasting or vigorous exercise depletes glycogen stores, making the body switch to de-novo glucose synthesis to&#x000a0;maintain blood levels of this monosaccharide.&#x000a0;Gluconeogenesis is the&#x000a0;process&#x000a0;that allows the body to&#x000a0;form glucose from non-hexose precursors, particularly glycerol, lactate, pyruvate, propionate, and glucogenic amino acids.<xref ref-type="bibr" rid="article-22307.r1">[1]</xref></p>
        <p>Gluconeogenesis essentially reverses&#x000a0;glycolysis (see <bold>Image</bold>. Gluconeogenesis). Four enzymes facilitate glucose synthesis by this pathway by&#x000a0;reversing 3&#x000a0;highly exergonic glycolytic steps, namely, pyruvate carboxylase, phosphoenol pyruvate carboxykinase (PEPCK),&#x000a0;fructose-1,6-bisphosphatase, and glucose-6-phosphatase. However, these enzymes are not present in all cell types. Therefore, gluconeogenesis can only occur in specific tissues.&#x000a0;In humans, gluconeogenesis takes place primarily in the liver and, to a lesser extent, the renal cortex.<xref ref-type="bibr" rid="article-22307.r2">[2]</xref></p>
        <p>This article discusses gluconeogenesis and its clinical correlates.</p>
      </sec>
      <sec id="article-22307.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Only a moderate amount of glucose can be synthesized by gluconeogenesis, but failure of this pathway is typically fatal.&#x000a0;Acute hypoglycemia can damage the brain and kidneys because of their dependence on glucose for fuel. Gluconeogenesis is also one of the body's main clearing mechanisms for the muscle and erythrocyte metabolite, lactic acid. Lactic acidosis arising from shock is associated with increased mortality risk.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK470202/">[14]</ext-link></p>
      </sec>
      <sec id="article-22307.s3" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>
<bold>Gluconeogenesis Reactions And Enzymes</bold>
</p>
        <p>The primary stimulus for gluconeogenesis is low blood glucose. Starting&#x000a0;with pyruvate, the reactions&#x000a0;involved in gluconeogenesis are the following:</p>
        <list list-type="order">
          <list-item>
            <p>In the mitochondrion, pyruvate carboxylase&#x000a0;converts pyruvate to oxaloacetate. Pyruvate carboxylase requires ATP and the coenzyme biotin for activation. This conversion is the first&#x000a0;step that reverses the nonequilibrium reaction catalyzed by the glycolytic enzyme&#x000a0;pyruvate kinase.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Oxaloacetate is converted to malate before it crosses the mitochondrial membrane. Malate is converted back to oxaloacetate once in the cytosol.</p>
          </list-item>
          <list-item>
            <p>In the cytosol,&#x000a0;PEPCK decarboxylates oxaloacetate, which then rearranges to form phosphoenol pyruvate (PEP).&#x000a0;PEPCK requires GTP and magnesium ions for activation. This&#x000a0;transformation is the second&#x000a0;step that reverses the nonequilibrium reaction catalyzed by pyruvate kinase.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Enolase hydrates PEP to form 2-phosphoglycerate.</p>
          </list-item>
          <list-item>
            <p>Phosphoglycerate mutase converts 2-phosphoglycerate to 3-phosphoglycerate.</p>
          </list-item>
          <list-item>
            <p>Phosphoglycerate kinase phosphorylates 3-phosphoglycerate to form 1,3-bisphosphoglycerate. This reaction requires ATP.</p>
          </list-item>
          <list-item>
            <p>Glyceraldehyde-3-phosphate dehydrogenase reduces 1,3-bisphosphoglycerate to glyceraldehyde 3-phosphate. Reduced nicotinamide adenine dinucleotide (NADH) is the electron donor.</p>
          </list-item>
          <list-item>
            <p>Triose phosphate isomerase isomerizes glyceraldehyde 3-phosphate to form dihydroxyacetone phosphate (DHAP).</p>
          </list-item>
          <list-item>
            <p>Aldolase combines glyceraldehyde 3-phosphate and&#x000a0;DHAP to form fructose 1,6-bisphosphate.</p>
          </list-item>
          <list-item>
            <p>Fructose-1,6-bisphosphatase dephosphorylates fructose 1,6-bisphosphate to form&#x000a0;fructose 6-phosphate. This step reverses the&#x000a0;nonequilibrium reaction catalyzed by the glycolytic enzyme phosphofructokinase-1.</p>
          </list-item>
          <list-item>
            <p>Phosphohexose isomerase converts fructose 6-phosphate to glucose 6-phosphate.</p>
          </list-item>
          <list-item>
            <p>Glucose-6-phosphatase dephosphorylates glucose 6-phosphate to form glucose, which&#x000a0;can enter the bloodstream freely.&#x000a0;This&#x000a0;last reaction&#x000a0;reverses the nonequilibrium reaction catalyzed by the glycolytic enzyme hexokinase.</p>
          </list-item>
        </list>
        <p>
<bold>Substrates Of Gluconeogenesis</bold>
</p>
        <p>The major substrates of gluconeogenesis are lactate, glycerol, and glucogenic amino acids.</p>
        <p>Lactate is&#x000a0;a product of anaerobic glycolysis.&#x000a0;This ATP-generating process occurs when&#x000a0;oxygen is limited, eg, during vigorous exercise or low-perfusion states. Cells that use this pathway, such as the erythrocytes, lack mitochondria&#x000a0;and&#x000a0;are not equipped for oxidative phosphorylation. The liver&#x000a0;uses lactate in the blood to produce glucose via gluconeogenesis. Glucose gets released into the bloodstream, travels back to the erythrocytes and exercising muscles,&#x000a0;and is metabolized back into&#x000a0;lactate. This process is&#x000a0;called the Cori cycle.<xref ref-type="bibr" rid="article-22307.r2">[2]</xref></p>
        <p>Glycerol comes from adipose tissue lipolysis. This process breaks down triglycerides to form&#x000a0;fatty acids and glycerol molecules. In the liver, glycerol kinase phosphorylates glycerol to form&#x000a0;glycerol phosphate. Glycerol phosphate dehydrogenase&#x000a0;oxidizes glycerol phosphate&#x000a0;into the glycolytic intermediate,&#x000a0;DHAP.<xref ref-type="bibr" rid="article-22307.r3">[3]</xref></p>
        <p>Glucogenic amino acids enter the gluconeogenesis pathway via the citric acid cycle (see <bold>Image</bold>. Glucogenic Amino Acids). The first step is the deamination of the glucogenic amino acids into &#x003b1;-ketoacids, which are substrates in the citric acid cycle. From there, these &#x003b1;-ketoacids are converted to&#x000a0;oxaloacetate, the substrate for PEPCK.</p>
        <p>
<bold>Regulation Of Gluconeogenesis</bold>
</p>
        <p>Gluconeogenesis reactions are highly endergonic and, thus, easily reversible. Controls at various levels ensure that each reaction moves forward until free glucose is produced.&#x000a0;Glucagon is the most important promoter of gluconeogenesis. Secondary ones include the catecholamines, growth hormone, cortisol, and gluconeogenic substrates.<xref ref-type="bibr" rid="article-22307.r4">[4]</xref><xref ref-type="bibr" rid="article-22307.r5">[5]</xref></p>
        <p>The pancreatic alpha cells secrete glucagon in response to falling blood glucose levels. This hormone increases the concentration of cyclic adenosine monophosphate (cAMP), which inactivates glycolytic enzymes&#x000a0;while activating gluconeogenic ones. Catecholamines produce the same effect by enhancing intracellular cAMP concentration.<xref ref-type="bibr" rid="article-22307.r6">[6]</xref><xref ref-type="bibr" rid="article-22307.r7">[7]</xref></p>
        <p>Insulin is a potent inhibitor of gluconeogenesis.<xref ref-type="bibr" rid="article-22307.r8">[8]</xref>&#x000a0;Falling insulin levels during fasting activate&#x000a0;gluconeogenesis and the processes that increase the availability of gluconeogenic substrates.<xref ref-type="bibr" rid="article-22307.r4">[4]</xref></p>
        <table-wrap id="article-22307.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Effect of Different Hormones on Key Glycolytic and Gluconeogenic Enzymes</title>
          </caption>
          <table style="border-color: black; width: 600px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr style="height: 27px;">
                <td style="width: 159.133px; height: 27px;" rowspan="1" colspan="1">
<bold>Enzyme</bold>
</td>
                <td style="width: 158.586px; height: 27px;" rowspan="1" colspan="1">
<bold>Effect of Glucagon and Catecholamines</bold>
</td>
                <td style="width: 158.281px; height: 27px;" rowspan="1" colspan="1">
<bold>Effect of Insulin</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 159.133px; height: 13px;" rowspan="1" colspan="1">Glycolysis</td>
                <td style="width: 158.586px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 158.281px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 159.133px; height: 35px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Glucokinase</p></list-item></list>
</td>
                <td style="width: 158.586px; height: 35px;" rowspan="1" colspan="1">&#x000a0;Inhibition</td>
                <td style="width: 158.281px; height: 35px;" rowspan="1" colspan="1">Induction</td>
              </tr>
              <tr style="height: 49px;">
                <td style="width: 159.133px; height: 49px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Phosphofructokinase-1</p></list-item></list>
</td>
                <td style="width: 158.586px; height: 49px;" rowspan="1" colspan="1">&#x000a0;&#x000a0;Inhibition</td>
                <td style="width: 158.281px; height: 49px;" rowspan="1" colspan="1">Induction</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 159.133px; height: 35px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Pyruvate kinase</p></list-item></list>
</td>
                <td style="width: 158.586px; height: 35px;" rowspan="1" colspan="1">&#x000a0;Inhibition</td>
                <td style="width: 158.281px; height: 35px;" rowspan="1" colspan="1">Induction</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 159.133px; height: 13px;" rowspan="1" colspan="1">Gluconeogenesis</td>
                <td style="width: 158.586px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 158.281px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 13.5px;">
                <td style="width: 159.133px; height: 13.5px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Pyruvate carboxylase</p></list-item></list>
</td>
                <td style="width: 158.586px; height: 13.5px;" rowspan="1" colspan="1">&#x000a0;Induction</td>
                <td style="width: 158.281px; height: 13.5px;" rowspan="1" colspan="1">&#x000a0;&#x000a0;Inhibition</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 159.133px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>PEPCK</p></list-item></list>
</td>
                <td style="width: 158.586px; height: 13px;" rowspan="1" colspan="1">Induction</td>
                <td style="width: 158.281px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Inhibition&#x000a0;</td>
              </tr>
              <tr style="height: 27px;">
                <td style="width: 159.133px; height: 27px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Fructose-1,6-bisphosphatase</p></list-item></list>
</td>
                <td style="width: 158.586px; height: 27px;" rowspan="1" colspan="1">Induction</td>
                <td style="width: 158.281px; height: 27px;" rowspan="1" colspan="1">&#x000a0;&#x000a0;Inhibition</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 159.133px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Glucose-6-phosphatase</p></list-item></list>
</td>
                <td style="width: 158.586px; height: 13px;" rowspan="1" colspan="1">Induction</td>
                <td style="width: 158.281px; height: 13px;" rowspan="1" colspan="1">&#x000a0;&#x000a0;Inhibition</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The alanine cycle,&#x000a0;aka the Cahill cycle, augments gluconeogenic glucose production during fasting.&#x000a0;In skeletal muscle, alanine aminotransferase (ALT) transfers an &#x003b1;-amino group from glutamate to pyruvate, producing alanine and &#x003b1;-ketoglutarate. Alanine is released from skeletal muscle and taken up by the liver for transamination back to pyruvate. Pyruvate can then be used for gluconeogenesis.<xref ref-type="bibr" rid="article-22307.r9">[9]</xref><xref ref-type="bibr" rid="article-22307.r10">[10]</xref></p>
      </sec>
      <sec id="article-22307.s4" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>During the first 18 to 24 hours of fasting, gluconeogenesis mostly occurs in the liver. Prolonged starvation forces the kidneys to assume as much as 20% of the total&#x000a0;glucose production by this pathway.&#x000a0;Only the liver and kidneys have the&#x000a0;gluconeogenic enzyme glucose-6-phosphatase and, thus, have the ability to convert&#x000a0;glucose 6-phosphate&#x000a0;into free glucose.<xref ref-type="bibr" rid="article-22307.r1">[1]</xref><xref ref-type="bibr" rid="article-22307.r2">[2]</xref></p>
      </sec>
      <sec id="article-22307.s5" sec-type="Function">
        <title>Function</title>
        <p>Gluconeogenesis maintains blood glucose levels during starvation. Some tissues in the human body rely almost exclusively on glucose as a metabolic fuel source. The brain, for example, requires approximately 120 g of glucose per day. Ketone bodies can serve as the brain's alternative fuel source. However, the testes, renal medulla, and erythrocytes cannot survive long periods without glucose.&#x000a0;Gluconeogenesis starts 4 to 6 hours after fasting begins, peaking after 24&#x000a0;when&#x000a0;hepatic glycogen is depleted.<xref ref-type="bibr" rid="article-22307.r1">[1]</xref><xref ref-type="bibr" rid="article-22307.r2">[2]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0730870100">[15]</ext-link></p>
      </sec>
      <sec id="article-22307.s6" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Von Gierke disease is an autosomal recessive condition notable for deficiency of the key gluconeogenic enzyme glucose-6-phosphatase. Gluconeogenesis is impaired, resulting in&#x000a0;fasting hypoglycemia. Glycogenolysis is also affected, as free glucose in the last step of this pathway needs the same enzyme for conversion&#x000a0;from&#x000a0;glucose 6-phosphate.&#x000a0;Other metabolic&#x000a0;abnormalities&#x000a0;that can manifest in von Gierke disease are hyperkalemia, hyperuricemia, and lactic acidosis.<xref ref-type="bibr" rid="article-22307.r11">[11]</xref></p>
      </sec>
      <sec id="article-22307.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Treating Hyperglycemia in Diabetes</bold>
</p>
        <p>Diabetes&#x000a0;may result&#x000a0;from impaired insulin production or decreased insulin sensitivity. Besides&#x000a0;stimulating glucose uptake from the bloodstream, insulin is also a potent gluconeogenesis inhibitor. Gluconeogenesis occurs at&#x000a0;an unusually rapid rate in insulin deficiency or insensitivity, increasing the risk of hyperglycemia in patients with diabetes mellitus.<xref ref-type="bibr" rid="article-22307.r1">[1]</xref></p>
        <p>Metformin, the first-line agent for&#x000a0;type 2 diabetes mellitus management, has been shown to suppress hepatic gluconeogenesis&#x000a0;by various mechanisms.&#x000a0;This drug&#x000a0;activates adenosine monophosphate-activated protein kinase (AMPK), which, in turn, inhibits hepatic lipogenesis and increases insulin sensitivity.&#x000a0;AMPK activation also increases cAMP breakdown, further&#x000a0;suppressing gluconeogenesis.<xref ref-type="bibr" rid="article-22307.r1">[1]</xref><xref ref-type="bibr" rid="article-22307.r12">[12]</xref></p>
        <p>Metformin also appears to directly inhibit glycerol-3-phosphate dehydrogenase, increasing&#x000a0;NADH levels.<xref ref-type="bibr" rid="article-22307.r1">[1]</xref><xref ref-type="bibr" rid="article-22307.r12">[12]</xref>&#x000a0;High intracellular NADH favors the formation of lactate over pyruvate by the&#x000a0;lactate dehydrogenase&#x000a0;reaction. Gluconeogenesis using lactate as a substrate cannot proceed without this molecule's conversion back to pyruvate.</p>
        <p>At high doses, metformin also inhibits complex I of the electron transport chain, the ATP production that drives highly endergonic processes like&#x000a0;gluconeogenesis.<xref ref-type="bibr" rid="article-22307.r1">[1]</xref></p>
        <p>
<bold>Hypoglycemia as a Result of Ethanol Consumption</bold>
</p>
        <p>Ethanol clearance from the body begins with its oxidation into&#x000a0;acetaldehyde by hepatic&#x000a0;alcohol dehydrogenase. This enzyme uses oxidized nicotinamide adenine dinucleotide (NAD+) as an electron acceptor. Aldehyde dehydrogenase oxidizes&#x000a0;acetaldehyde further into acetate, which is readily excreted by the body.&#x000a0;Aldehyde dehydrogenase also requires NAD+ as a cofactor.&#x000a0;Thus,&#x000a0;ethanol&#x000a0;metabolism results in NADH accumulation.<xref ref-type="bibr" rid="article-22307.r13">[13]</xref></p>
        <p>As previously mentioned, high intracellular NADH&#x000a0;increases&#x000a0;lactic acid formation, which can inhibit gluconeogenesis. Thus, heavy ethanol consumption&#x000a0;can lead to both lactic acidosis and hypoglycemia.<xref ref-type="bibr" rid="article-22307.r13">[13]</xref></p>
        <p>
<bold>Hypoglycemia in the Preterm Infant</bold>
</p>
        <p>Preterm infants are particularly&#x000a0;at risk of developing hypoglycemia. Low-birth-weight neonates have limited glycogen and fat stores but also express gluconeogenic enzymes at suboptimal levels. Preterm infants' energy stores can diminish quickly,&#x000a0;as they cannot mount&#x000a0;an adequate&#x000a0;counterregulatory response.<xref ref-type="bibr" rid="article-22307.r4">[4]</xref></p>
      </sec>
      <sec id="article-22307.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22307&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22307">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22307/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22307">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22307.s9">
        <fig id="article-22307.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Glucogenic Amino Acids. This illustration shows&#x000a0;how the glucogenic amino acids enter the Krebs cycle. Image courtesy Dr Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gluconeogenesis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22307.s10">
        <title>References</title>
        <ref id="article-22307.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Unraveling the Regulation of Hepatic Gluconeogenesis.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>802</fpage>
            <pub-id pub-id-type="pmid">30733709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Chacko</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Sunehag</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Haymond</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Measurements of Gluconeogenesis and Glycogenolysis: A Methodological Review.</article-title>
            <source>Diabetes</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>12</issue>
            <fpage>3996</fpage>
            <page-range>3996-4010</page-range>
            <pub-id pub-id-type="pmid">26604176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>da Silva</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Rebelo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>JPG</given-names>
              </name>
              <name>
                <surname>Soveral</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Revisiting the metabolic syndrome: the emerging role of aquaglyceroporins.</article-title>
            <source>Cell Mol Life Sci</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>11</issue>
            <fpage>1973</fpage>
            <page-range>1973-1988</page-range>
            <pub-id pub-id-type="pmid">29464285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shekhawat</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia in the preterm neonate: etiopathogenesis, diagnosis, management and long-term outcomes.</article-title>
            <source>Transl Pediatr</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>335</fpage>
            <page-range>335-348</page-range>
            <pub-id pub-id-type="pmid">29184814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bankir</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bouby</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Speth</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Velho</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crambert</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Glucagon revisited: Coordinated actions on the liver and kidney.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>146</volume>
            <fpage>119</fpage>
            <page-range>119-129</page-range>
            <pub-id pub-id-type="pmid">30339786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Droppelmann</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>S&#x000e1;ez</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Asenjo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Y&#x000e1;&#x000f1;ez</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Rocha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Concha</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Grez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guinovart</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Slebe</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>A new level of regulation in gluconeogenesis: metabolic state modulates the intracellular localization of aldolase B and its interaction with liver fructose-1,6-bisphosphatase.</article-title>
            <source>Biochem J</source>
            <year>2015</year>
            <month>Dec</month>
            <day>01</day>
            <volume>472</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-37</page-range>
            <pub-id pub-id-type="pmid">26417114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borrebaek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bremer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Davis-Van Thienen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The effect of glucagon on the carbon flux from palmitate into glucose, lactate and ketone bodies, studied with isolated hepatocytes.</article-title>
            <source>Int J Biochem</source>
            <year>1984</year>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>841</fpage>
            <page-range>841-4</page-range>
            <pub-id pub-id-type="pmid">6468742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kamikubo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goda</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Insulin-induced inhibition of gluconeogenesis genes, including glutamic pyruvic transaminase 2, is associated with reduced histone acetylation in a human liver cell line.</article-title>
            <source>Metabolism</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>71</volume>
            <fpage>118</fpage>
            <page-range>118-124</page-range>
            <pub-id pub-id-type="pmid">28521864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarabhai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roden</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hungry for your alanine: when liver depends on muscle proteolysis.</article-title>
            <source>J Clin Invest</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>129</volume>
            <issue>11</issue>
            <fpage>4563</fpage>
            <page-range>4563-4566</page-range>
            <pub-id pub-id-type="pmid">31545302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatazawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kamei</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>PGC-1&#x003b1; regulates alanine metabolism in muscle cells.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>e0190904</fpage>
            <pub-id pub-id-type="pmid">29315328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bali</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>El-Gharbawy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pendyal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kishnani</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <chapter-title>Glycogen Storage Disease Type I</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bean</surname>
                <given-names>LJH</given-names>
              </name>
              <name>
                <surname>Gripp</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2006</year>
            <month>4</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">20301489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hundal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Krssak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lebon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chandramouli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Inzucchi</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Schumann</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Landau</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Mechanism by which metformin reduces glucose production in type 2 diabetes.</article-title>
            <source>Diabetes</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>12</issue>
            <fpage>2063</fpage>
            <page-range>2063-9</page-range>
            <pub-id pub-id-type="pmid">11118008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22307.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Sonntag</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Montminy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>ATF3 mediates inhibitory effects of ethanol on hepatic gluconeogenesis.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2015</year>
            <month>Mar</month>
            <day>03</day>
            <volume>112</volume>
            <issue>9</issue>
            <fpage>2699</fpage>
            <page-range>2699-704</page-range>
            <pub-id pub-id-type="pmid">25730876</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
